[1,1'-Biphenyl]-4-hexanol | 157126-36-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [1,1'-Biphenyl]-4-hexanol
• 英文别名: 6-(1,1'-biphenyl)hexan-1-ol；6-(biphenyl-4-yl)hexan-1-ol；6-(biphenyl-4-yl)hexanol；6-(4-phenylphenyl)hexan-1-ol
• CAS: 157126-36-8
• 化学式: C₁₈H₂₂O
• 分子量: 254.372
• InChiKey: SVOHJRSLZWMREV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  [1,1'-Biphenyl]-4-hexanol 在 potassium dihydrogenphosphate 、 N-溴代丁二酰亚胺(NBS) 、 sodium methylate 、 三苯基膦 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.59h， 生成 Methyl 3-cyano-3-hydroxy-4-[6-(4-phenylphenyl)hexylsulfanyl]butanoate
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w
• 作为产物：
  描述：

  4-羧丁基三苯基溴化膦 在 platinum(IV) oxide 氢气 、 二异丁基氢化铝 、 dimsyl sodium 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 2.0h， 生成 [1,1'-Biphenyl]-4-hexanol
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w

文献信息

• Zwitterionic Sulfobetaine Inhibitors of Squalene Synthase
  作者：Thomas A. Spencer、Thomas J. Onofrey、Reginald O. Cann、Jonathon S. Russel、Laura E. Lee、Daniel E. Blanchard、Alfredo Castro、Peide Gu、Guojian Jiang、Ishaiahu Shechter

  DOI：10.1021/jo981617q

  日期：1999.2.1

  A substantial number of sulfobetaines (e.g., 10) have been synthesized and evaluated as inhibitors of squalene synthase (SS) on the basis of the idea that their zwitterionic structure would have properties conducive both to binding in the active site and to passage through cell membranes. When the simple sulfobetaine moiety is incorporated into compounds containing hydrophobic portions like those in

  已经合成了大量的磺基甜菜碱（例如10种），并根据其两性离子结构具有有助于在活性位点结合和通过细胞膜通过的特性，被认为是鲨烯合酶（SS）的抑制剂。 。当将简单的磺基甜菜碱部分掺入含有疏水部分的化合物中时，如法呢基二磷酸酯（1）或角鲨烯二磷酸酯（2）中的那些，确实在大鼠肝微粒体测定中观察到了SS的抑制作用。例如，法呢基化磺基甜菜碱10具有抑制SS的IC（50）＝10μM，而芳香族衍生物35具有IC（50）＝2μM。研究了多种结构修饰，例如化合物43、52、76、85、91、99、111和115。不幸，
• 1,3-benzenedimethanamines useful as central nervous system active agents
  申请人：Lilly Industries Limited

  公开号：US05428065A1

  公开（公告）日：1995-06-27

  Pharmaceutical compounds of the formula: ##STR1## R.sup.1 to R.sup.8 are each hydrogen or C.sub.1-4 alkyl, m, n and p are each 0, 1, or 2, q is 0, 1, 2 or 3, X and Z are each C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, nitro, cyano, halo, trihalomethyl, carboxy, C.sub.1-4 alkoxy-carbonyl or phenyl, and in addition z, together with the phenyl ring to which it is attached, can be: ##STR2## Y is --O--, --S-- or --CH.sub.2 --, V is --(CH.sub.2).sub.r -- or --(CH.sub.2).sub.r S-- where r is 1 to 15, and W is hydrogen or optionally substituted phenyl; and salts thereof.

  药物化合物的公式为：##STR1## R.sup.1到R.sup.8分别为氢或C.sub.1-4烷基，m、n和p分别为0、1或2，q为0、1、2或3，X和Z分别为C.sub.1-4烷基、C.sub.1-4烷氧基、羟基、硝基、氰基、卤素、三卤甲基、羧基、C.sub.1-4烷氧基羰基或苯基，另外z与连接它的苯环一起可以是：##STR2##Y为--O--、--S--或--CH.sub.2--，V为--(CH.sub.2).sub.r--或--(CH.sub.2).sub.r S--，其中r为1到15，W为氢或可选择取代的苯基；及其盐。
• 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Tsubouchi Hidetsugu

  公开号：US20060094767A1

  公开（公告）日：2006-05-04

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物，其通式如下：其中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表—OR3或类似的基团，R3代表氢原子、C1-C6烷基或类似的基团，或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环，其通式为（H）：其中，R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
• Substituted m-xylylene diamines for the treatment of diseases of the central nervous system
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0645370A1

  公开（公告）日：1995-03-29

  Pharmaceutical compounds of the formula: in which A is B is R¹ to R⁸ are each hydrogen or C₁₋₄ alkyl, m, n and p are each 0, 1, or 2, q is 0, 1, 2 or 3, X and Z are each C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxy, nitro, cyano, halo, trihalomethyl, carboxy, C₁₋₄ alkoxy-carbonyl or phenyl, and in addition Z, together with the phenyl ring to which it is attached, can be: Y is -O-, -S- or -CH₂-, V is -(CH₂)r- or -(CH₂)rS- where r is 1 to 15, and W is hydrogen or optionally substituted phenyl; and salts thereof.

  式中的药物化合物： 其中 A 为 B 是 R¹至R⁸各自为氢或C₁₋₄烷基，m、n和p各自为0、1或2，q为0、1、2或3，X和Z各自为C₁₋₄烷基、C₁₋₄烷氧基、羟基、硝基、氰基、卤代、三卤甲基、羧基、C₁₋₄烷氧基-羰基、硝基、氰基、卤代、三卤甲基、羧基、C₁₋₄ 烷氧羰基或苯基，此外，Z 及其所连接的苯基环可以是： Y为-O-、-S-或-CH₂-，V为-(CH₂)r-或-(CH₂)rS-，其中 r 为 1 至 15，W 为氢或任选取代的苯基；及其盐类。
• 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1555267A1

  公开（公告）日：2005-07-20

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R2 represents a group -OR3 or the like, and R3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R1 and -(CH2)nR2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and a typical acid-fast bacteria.

  本发明提供了由以下通式代表的 2，3-二氢-6-硝基咪唑并[2，1-b]恶唑化合物： 其中R1代表氢原子或C1-C6烷基，n代表0至6的整数，R2代表基团-OR3或类似基团，R3代表氢原子、C1-C6烷基或类似基团，或者R1和-(CH2)nR2可以通过氮原子与相邻的碳原子相互结合，从而形成通式(H)代表的螺环： 其中 R41 为氢、C1-C6 烷基或类似基团。本化合物对结核分枝杆菌、多重耐药结核分枝杆菌和典型的耐酸细菌有很好的杀菌作用。